MedTrace Logo

Quality of Life Outcomes for Ulipristal Acetate and Tranexamic Acid in the Management of Heavy Menstrual Bleeding

NCT03027973 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-01-28

No results posted yet for this study

Summary

This study compares two treatments for the management of heavy menstrual bleeding, ulipristal acetate (UPA) and tranexamic acid (TEA), on health-related quality of life. Half of the participants will receive UPA and a placebo, and the other half will receive TEA and a placebo.

Conditions

  • Heavy Menstrual Bleeding

Interventions

DRUG

UPA

Experimental drug

DRUG

TEA

Active comparator

DRUG

Placebo (for UPA)

Sugar pill manufactured to mimic UPA 5 mg

DRUG

Placebo (for TEA)

Sugar pill manufactured to mimic TEA 500mg

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Almereau Prollius, MD · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
51 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2020-01-31
Completion
2020-01-17

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03027973 on ClinicalTrials.gov